



Poster Session 2
5:30 – 7:00 p.m.
Wednesday, December 11

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| P2-01-01: Lifestyle Linked Biomarker is Associated with Poor Prognosis in Estrogen Receptor Negative Breast Cancer | Lindsay Peterson |
| P2-01-02: Patient’s Preference for Shared Decision Making-Based Distant Metastasis Surveillance and Its Effect on the Quality of Life: A Prospective Pragmatic Trial | Ji-Jung Jung |
| P2-01-03: Is trastuzumab associated with new-onset hypertension in adolescents and young adults with breast cancer? | Candice Sauder |
| P2-01-04: Impact of Mobile Healthcare Apps on Patient-Reported Quality of Life after Breast Cancer Surgery: A Randomized Controlled Trial | Yung-Huyn Hwang |
| P2-01-05: Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2– Metastatic Breast Cancer | Hope S. Rugo |
| P2-01-06: Supportive care concerns of young women living with metastatic breast cancer from an ongoing prospective virtual intervention | Kate E Dibble |
| P2-01-07: The Co-Occurrence of Obesity and Cancer-Related Fatigue and Their Combined Impact on Physical Function in a Nationwide RCT of 456 Breast Cancer Survivors (a URCC NCORP Study). | Lindsey Mattick |
| P2-01-08: Follow-up in Early and Locally Advanced Breast Cancer Patients: An EORTC QLQ-BCG- ROG study. | Vesna Bjelic-Radiscic |
| P2-01-09: Patient-reported outcomes in premenopausal breast cancer patients with or without ovarian suppression therapy – a subgroup analysis from a Brazilian prospective cohort | Natalia Nunes |
| P2-01-10: A real-world evidence study of an online Mindfulness-Based Stress Reduction intervention: Effects on the symptomatic burden of patients with breast cancer | Cynthia Villarreal-Garza |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| P2-01-11: Supportive Care Service Utilization Among Long Term Metastatic Breast Cancer Survivors | Ashley Pariser Davenport |
| P2-01-12: Association of Employment Characteristics and Food Insecurity Risks among Women with Breast Cancer | Michael Halpern |
| P2-01-13: Palliative Care Use and End-of-Life Care Quality in HR+/HER2- Metastatic Breast Cancer | Julia Cohn |
| P2-01-14: Impact of Psychological Support on Quality of Life, Coping Strategies, and Anxiety and Depression in Breast Cancer Patients: A Comparative Randomized Study | Marina Campione |
| P2-01-15: Survivorship attributes in women with hormone receptor positive breast cancer at long term follow-up in the CLEAR Study of Late Recurrence. | Ana Elisa Lohmann |
| P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE project | Rodrigo Sánchez-Bayona |
| P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy & a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial | Maxwell Lloyd |
| P2-01-19: Measurement of ADC Targets HER2 and TROP2 in Breast Cancer for Accuracy and Selection | NAY CHAN |
| P2-01-20: Impact of Exercise on Immune Biomarkers in Benign Breast Tissue from Women with High Mammographic Breast Density (MBD) | Jennifer Ligibel |
| P2-01-21: Baseline circulating tumor cells (CTCs) predict for progression-free survival (PFS) after ablation on NRG-BR002, a randomized phase II/III study of ablation vs. standard systemic therapy care (SOC) for oligometastatic breast cancer (OMBC). | Wendy Woodward |
| P2-01-22: NSABP B-31 confirms the prognostic value of the NeoALTTO-developed S5 genomic classifier | Katherine Pogue-Geile |
| P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC | Xixuan Zhu |
| P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial | Ulrike Heber |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| P2-01-25: Circulating tumor DNA clearance by neoadjuvant chemotherapy or breast surgery detected using an ultrasensitive ctDNA MRD assay in early breast cancer | Luc Cabel |
| P2-01-26: Carboplatin added to neoadjuvant chemotherapy in a randomized phase II study: Complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer. | Olav Engebraaten |
| P2-01-27: Utility of Plasma Circulating DNA Tumor Fraction in Bone-Only Metastatic Breast Cancer: A Real-world Outcomes Study | Deloris Veney |
| P2-01-28: Expression of Antibody-Drug Conjugate targets in tumor and normal tissue from patients with metastatic breast cancer | Kristien Borremans |
| P2-01-29: Prognostic value of circulating tumor DNA in metastatic breast cancer | Luc Cabel |
| P2-01-30: Gene Expression patterns in early ER+/HER2- breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial | Evangelos Tzoras |
| P2-02-01: Enhancing chemotherapy sensitivity in triple-negative breast cancer through knockdown of the 'Dark' druggable gene SCYL3 | Hannah Engebretson |
| P2-02-02: CHEMOTHERAPEUTIC TOPOISOMERASE 2 POISONS GENERATE TREX1 RESISTANT DNA FRAGMENTS THAT INDUCE A POTENT cGAS/STING RESPONSE | Kienan Savage |
| P2-02-03: The RAR gamma nuclear receptor agonist IRX5010 has combination inhibitory effects with an anti-PDL-1 checkpoint inhibitor on the growth of EMT-6 triple negative breast cancer | Martin Sanders |
| P2-02-04: Investigating Semaphorin7a in Mammary Gland Involution and Postpartum Breast Tumorigenesis | Lauren Cozzens |
| P2-02-05: Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models | Stefano Rossetti |
| P2-02-06: Molecular heterogeneity in adjacent normal tissue among Chinese breast cancer patients | Hela Koka |
| P2-02-07: Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions | Stefano Rossetti |
| P2-02-08: Chromosome 8q gain-related transcription factor MYBL1 is a critical regulator in triple-negative breast cancer | Akihiro Fujimoto |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| P2-02-09: Novel Intramolecular BRCT Domain Interaction with ECT2 C-terminal Intramolecular Interaction Domain Regulates GEF Activity and Tumorigenesis | Jinyu Lu |
| P2-02-10: Inhibition of the Kif11 mitotic protein kills TP53-mutant triple-negative breast cancer cells | Amanda Lanier |
| P2-02-11: Unveiling the subtype-specific role of PTPRK in triple-negative breast cancer: Implications for targeted therapies | Xiangyi Liu |
| P2-02-13: Metformin prevents tumor cell growth and invasion of human hormone receptor positive breast cancer (HR+BC) cells via FOXA1 inhibition | SeungBaek Lee |
| P2-02-14: C1QL1 inhibits breast cancer through HSP90 α /VCP-ERS/UPR axis | Ningning Zhang |
| P2-02-15: Engineered macrophages secreting TRAIL achieve immunotherapy for triple-negative breast cancer by inhibiting the Wnt/ β -catenin signaling pathway | Chuangui Song |
| P2-02-16: Therapeutic Decision-Making in Breast Cancer: The Contribution of Artificial Intelligence | Marina Campione |
| P2-02-17: Race and outcomes in HR+/HER2- breast cancer: how tissue morphology and molecular pathways contribute to worse outcomes in Black women | Daniel Cook |
| P2-02-18: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project | Brittany McKelvey |
| P2-02-19: Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy | Anran Li |
| P2-02-20: Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Intraoperative Fluorescence Multi-modal Imaging | He Sun |
| P2-02-21: Predicting HER2-targeting antibody-drug conjugate dosing regimens and quantifying immune system contributions to efficacy using agent-based computational modeling | Melissa Calopiz |
| P2-02-22: BCM PDX Insights Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management to Facilitate Pre-clinical Studies in Breast Cancer | Michael Lewis |
| P2-02-23: Open | |
| P2-02-24: Evaluating ChatGPT as an educational resource for patients with Breast cancer: A preliminary investigation | Zunairah Shah |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| P2-02-25: Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis | Casey Stowers |
| P2-02-26: Development of AI diagnosis of immunohistochemistry for ER and HER2 in breast cancer. | Kaori Terata |
| P2-02-27: Automating Breast Cancer Relapse Identification in Pathology Reports Using Natural Language Processing | Jaimie Lee |
| P2-02-28: Challenges and Opportunities in Early Diagnosis of Breast Cancer: Utilizing Clinical Decision Support Platforms for Improved Detection | Bea Bakshi |
| P2-02-29: AI-based Clinical Decision Support System (CDSS) for predicting response to primary systemic therapy in early breast cancer: multimodal modeling and pathology contribution. | Barbara Bussels |
| P2-03-01: Sexual health in unpartnered women after breast cancer: Report from a joint analysis of two international multi-site prospective cohorts of young breast cancer survivors | Sharon Bober |
| P2-03-02: Fertility and ovarian function preservation in young women with breast cancer: A comparative analysis of two prospective cohort studies in Mexico and Italy | Cynthia Villarreal-Garza |
| P2-03-03: Aromatase inhibitor (AI) use in a phase I, single arm, prospective study to evaluate the treatment of genitourinary syndrome of menopause (GSM) with platelet rich plasma (PRP) in women with a history of breast cancer. | Anita Chen |
| P2-03-04: Assessing and Addressing the Distinct Psychosocial Needs of Young Women with Breast Cancer | Shari Goldfarb |
| P2-03-05: AI-Powered Breast Cancer Survivorship Support: A Comparative Analysis of ChatGPT and Gemini in Providing Evidence-Based Lifestyle Guidance | Jasmin Hundal |
| P2-03-06: Factors Associated with Pregnancy and Postpartum Treatment After Endocrine Therapy Interruption in Breast Cancer Patients | Risa Kasahara |
| P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study | Sarah Premji |
| P2-03-08: Influence of Work Schedule Flexibility on Nutrition and Physical Activity Among Employed Breast Cancer Survivors | Jasmin Hundal |
| P2-03-09: Breast Cancer Surgery and Its Quality-of-Life Outcomes: A Study of São Paulo Public Employees | Marcelo Antonini |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| P2-03-10: Functional Disability and Adverse Mental Health Outcomes among Breast Cancer Survivors: A US National Survey Study | Jincong Freeman |
| P2-03-11: Health-Related Quality of Life in BREAST trial (Brazilian outcome for Metastatic Breast Cancer): clinical outcomes of HR+, HER2+ breast cancer and its relationship with access to healthcare in Brazil | Luciola Leite de Barros |
| P2-03-12: Reducing Stress and Improving Quality of Life for Adult Breast Cancer Patients via delivery of monthly non-medical essential services for up to six months during treatment | Danna Remen |
| P2-03-13: Quality of life in young Hispanic women with breast cancer: Long-term results from a large prospective cohort | Cynthia Villareal-Garzac |
| P2-03-14: PATIENT REPORTED OUTCOMES AND LYMPHEDEMA IN NODE-POSITIVE BREAST CANCER IN THE EARLY POSTOPERATIVE PERIOD AFTER NEOADJUVANT CHEMOTHERAPY IN THE PROSPECTIVE NEOSENTITURK-trial MF18-03 | Neslihan Cabioglu |
| P2-03-15: Identifying pre-habilitation targets for the mitigation of long-term side effects of chemotherapy in patients with early breast cancer | Lyndsay Cooper |
| P2-03-16: Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the Phase 3 CAPItello-291 clinical trial | Javier Cortés |
| P2-03-17: Targeting NR2F2 overcomes multiple forms of endocrine resistance | Yanyan Cai |
| P2-03-18: Lymph node metastasis of breast cancer: subclonal selection for high lipid metabolism from the primary tumor | Yue Zhou |
| P2-03-19: Capiasertib-fulvestrant for patients w/ HR-pos/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial | Komal Jhaveri |
| P2-03-20: Correlation of cell cycle arrest and intrinsic subtype with pathologic nodal status after neoadjuvant endocrine therapy – results from the Palbociclib and Endocrine therapy for Lobular breast cancer Preoperative Study | Anna Weiss |
| P2-03-21: Longitudinal Monitoring of ctDNA for Disease Surveillance in Older Women with ER+ Breast Cancer on Primary Endocrine Therapy to Facilitate Surgical De-Escalation: A Prospective, Pragmatic, Hybrid-Decentralized Trial with Correlative Analyses | Neil Carleton |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| P2-03-22: Shallow whole genome sequencing of cell free DNA to predict response to CDK4/6 inhibitor treatment in ER+/HER2-metastatic breast cancer | Olga Oikonomidou |
| P2-03-23: Charting the longitudinal mutational landscape of triple negative breast cancer | Olga Oikonomidou |
| P2-03-24: Cost-Effectiveness of CYP2D6 Genotyping in the Management of Tamoxifen Therapy for Breast Cancer Patients: A Focus on Adverse Events | Isabel Blancas |
| P2-03-25: Characterization of patritumab deruxtecan activity in breast cancer (BC) patient-derived xenograft (PDX) models | Andreu Òdena |
| P2-03-26: Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer (eTNBC/mTNBC): primary results and pathology insights from the global retrospective observational VANESSA study | Corrado D'Arrigo |
| P2-03-27: Prevalence of actionable genomic alterations (GA) and predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitor (ICI) effectiveness in HR(+)HER2(-) metastatic breast cancer (MBC) | Mariya Rozenblit |
| P2-03-28: Immune-based gene expression signature determines clinical efficacy of CDK4/6i in HR+HER2- breast cancer | Ester Ballana |
| P2-03-29: Upregulation of senescence signatures and interferon-signalling after short-term pre-operative CDK4/6 inhibitor – gene expression analysis from the POP and ABC-POP trials | Julia Dixon-Douglas |
| P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial | Daniel Egle |
| P2-04-01: MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells | Nami Yamashita |
| P2-04-02: TRIB3 regulates lipophagy and drives the metastasis of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway | ziron g jiang |
| P2-04-03: Progesterone Receptor-Stimulated MicroRNAs Regulate Breast Cancer Proliferation | Motoki Takaku |
| P2-04-04: Integrated stress response-upregulated mitochondrial SLC1A5var enhances glucose dependency of human breast cancer cells | Sheng-Fan Wang |
| P2-04-05: The dynein regulator LIS1 maintains cell cycle progression and DNA integrity in TNBC, and can be targeted to improve paclitaxel response | Parth Majmudar |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| P2-04-06: Enhancement of TGF- β Receptor Inhibitor Efficacy through CD44 Suppression in Claudin-low Breast Cancer | Ryoichi Matsunuma |
| P2-04-07: Dual function of PRAK in TP53-associated breast cancer metastasis | Jingjing Liu |
| P2-04-08: Functions of KLF5 in the cell cycle and breast cancer cell proliferation | Xiaoyun Mao |
| P2-04-09: A Novel Role of IP6K2 in Regulating Host Cell Death through p21-mediated cell cycle arrest during HSV-1 oncolytic virus Therapy | Zhijian Huang |
| P2-04-10: ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ER α Stabilization | Han Li |
| P2-04-11: Selective Pre-clinical Targeting of CD44+ ADAR1+ Triple Negative Breast Cancer | Wenxue Ma |
| P2-04-12: JAM A expression and its clinical/prognostic value in breast cancer | Yufei Lou |
| P2-04-13: DIFFERENTIAL SUSCEPTIBILITY OF MESENCHYMAL-LIKE AND BASAL-LIKE TRIPLE NEGATIVE BREAST CANCER CELLS TO STANDARD OF CARE TREATMENT | Ngoc Bao Vuong |
| P2-04-14: Activation of Target X by Del-1 regulates the progression of TNBC | byeongju kang |
| P2-04-15: Diagnostic potential of disseminated and circulating cancer cells: A case study of a 34-years-old patient with rapidly progressing breast cancer. | Jonas Roth |
| P2-04-16: Artificial intelligence can extract important features for diagnosing axillary lymph node metastasis in early breast cancer using contrast-enhanced ultrasonography | Tomohiro Oshino |
| P2-04-17: The MIRACCL Portal for Comparing Patient and PDX Response Using Cancer Image Features and Genomics in Co-Clinical Breast Cancer Trials | Michael Lewis |
| P2-04-18: Unlocking the Complete Blood Count as a Risk Stratification Tool for Breast Cancer Using Machine Learning: A Large Scale Retrospective Study | Pedro Henrique Souza |
| P2-04-19: Identification and Validation of Novel Necroptosis-Related lncRNAs for Prognostic Prediction in Breast Cancer | Zhijian Huang |
| P2-04-20: Advances and Detection Methods of Metachronous Bilateral Breast Cancer Detection Using AI-Assisted Mammography for Japanese women | Mio Adachi |
| P2-04-21: Dynamic reporting of treatment related symptoms via ePROs can reversely identify the type of underlying cancer | Andreas Trojan |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| P2-04-22: Predictive Modeling of Cancer Treatment-Related Cardiac Events in Breast Cancer Patients: Utilizing Dosiomic and Radiomic Features with Machine Learning | Sefika Dincer |
| P2-04-23: Analytical validation of a high-definition tumor-informed MRD assay demonstrates robust detection at low tumor fractions common in breast cancer | Ashley Acevedo |
| P2-04-24: CINDERELLA Clinical Trial (NCT05196269): initial Insights into Patient Engagement with an Artificial Intelligence-Based Healthcare Application for Enhancing Breast Cancer Locoregional Treatment Decisions | André Pfob |
| P2-04-25: Different Pyroptosis Phenotype within Breast Cancer Possess Distinctive Prognosis and Tumor Immune Microenvironment | Ye Hong |
| P2-04-26: Predicting the prognosis and immunotherapeutic response of triple-negative breast cancer by constructing a prognostic model based on CD8T cell-related immune genes | Zhijian Huang |
| P2-04-27: Development & Validation of RSC4All: an Artificial Intelligence-driven Machine Learning Nomogram Enhanced with Synthetic Data to Predict RSClin® Results & Guide Adjuvant Treatment of Node-negative HR-positive/HER2-negative Early Breast Cancer | Flavia Jacobs |
| P2-04-28: Signal Processing Techniques for Investigating the role of Viral Infections in APOBEC3 Enzymes in Tumor Tissue Biopsies | Mohadeseh Soleimanpour |
| P2-04-29: Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: A SEER population-based study | ziron g jiang |
| P2-04-30: Harnessing Technology: A Comparative Study of AI versus Manual Scoring in HER2 Ultra-low Breast Cancer | Jeppe Thagaard |
| P2-05-01: Telemedicine in physical therapy after axillary surgery for early breast cancer | Hans-Christian Kolberg |
| P2-05-02: IDENTIFICATION OF MOST COMMON CONCERNS IN BREAST CANCER SURVIVORS FROM 2019-2023 IN THE MRW LIFE SURVIVORSHIP PROGRAM | Poornima Saha |
| P2-05-03: Work Reintegration After Breast Cancer Surgery in São Paulo Public Employees: a cross-sectional observational study. | Marcelo Antonini |
| P2-05-04: Associations between Hearing/Vestibular Problems and Levels of Physical Function Impairment among Breast Cancer Survivors in a Multiethnic Study Cohort | Jincong Freeman |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| P2-05-05: Associations among BMI and patient-reported body image dissatisfaction during immediate autologous breast reconstruction: A prospective longitudinal evaluation | Sara Bouhali |
| P2-05-06: Contemporary media – highlighting a podcast hosted by a breast cancer survivor – to disseminate breast cancer education in a credible, patient-friendly format. | Molly Lindquist |
| P2-05-07: Combination treatment to prevent and treat oxidative damage to neuronal cells | Matthew Koury |
| P2-05-08: QUALITY OF LIFE OF PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY: A LOOK AT SEXUALITY | FABIANA MAKDISSI |
| P2-05-09: Mindfulness as effective complementary therapy in the management of Breast Cancer (BC) | Maria-Eva Perez-Lopez |
| P2-05-10: Depression and anxiety in patients with breast cancer receiving radiotherapy: A prospective longitudinal study | Shi-Jia Wang |
| P2-05-11: A prospective cohort study of real-world patient-reported outcomes in HER2-positive early breast cancer patients receiving (neo) adjuvant anti-HER2 based therapy: the preliminary results at 2-cycle treatment | Ke-Da YU |
| P2-05-12: Experience and perceptions with a phone-based weight loss intervention among survivors of breast cancer (BC) in France: a qualitative study within a randomized clinical trial (RCT). | Antonio Di Meglio |
| P2-05-13: QUALITY OF SEXUAL LIFE IN YOUNG WOMEN WITH BREAST CANCER IN THE MEDICAL ONCOLOGY SERVICE AT THE HOSPITAL REGIONAL ISSSTE LEON | CARMEN GUADALUPE BERMUDEZ BARRIENTOS |
| P2-05-15: Challenges and Communication Gaps in Adjuvant Endocrine Therapy for HR+ Breast Cancer Patients in Russia: Insights from an online Survey | Anastasia Danilova |
| P2-05-16: Interrogating serum thymidine kinase activity with CDK4/6 inhibitor-based therapies: real-world experience in the metastatic and adjuvant setting | Agnieszka Witkiewicz |
| P2-05-17: The predictive and prognostic value of 18F-FES PET/CT in patients with advanced breast cancer treated with endocrine therapy with cyclin-dependent kinase 4/6 inhibitor | Hye Hyun Jeong, Jae Ho Jeong |
| P2-05-18: Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancer | Raquel Gómez-Bravo |
| P2-05-19: An ICG-labeled Novel Trop2 Targeting Peptide for In Vivo and Ex Vivo NIR-II Fluorescence Imaging-guided Breast Cancer Precise Surgery | Kangliang Lou |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| P2-05-20: Tissue-free minimal residual disease testing in 2,000 consecutive patients with breast cancer: real-world data and case report | Tanmayi Pai |
| P2-05-21: BRCA1/2 alterations in circulating tumor DNA: correlation with germline origin and impact on survival in breast cancer. | Letizia Pontolillo |
| P2-05-22: Plasma proteomic profiling of early recurrence of breast cancer | Anupama Praveen Kumar |
| P2-05-23: Inhibition of de novo fatty acid synthesis demonstrates broad synergistic effects with anti-cancer therapy, alters cellular lipid composition and induces endoplasmic reticulum stress | Naing Lin Shan |
| P2-05-24: Impact of the gut microbiome on immune-related adverse events (irAE) in HR+/HER2- locally advanced or metastatic breast cancer (MBC) patients (pts) receiving palbociclib, endocrine therapy, and pembrolizumab | Alexis LeVee |
| P2-05-25: Comparative Study of Droplet-digital PCR and Ultra-sensitive NGS Assay for ctDNA Profiling in Breast Cancer | Binggang Xiang |
| P2-05-26: Differential TROP2 expression patterns among inflamed tumor microenvironments in HER2-negative breast cancer | Mai Onishi |
| P2-05-27: Revealing prognostic subtypes and related model of early-stage TNBC | Peifen FU |
| P2-05-28: High throughput analysis in HER2 positive locally advanced breast cancer (BC): pathological complete response (pCR) and mutational status. | Ida Paris |
| P2-05-29: Orally bioavailable cyclin A/B-RxL inhibitors elicit antitumor activity in breast cancer patient-derived xenograft models | Cristina Molina-Gutiérrez |
| P2-05-30: Ki-67 dynamics during neoadjuvant treatment of breast cancer and their added prognostic value to the Neo-Bioscore model: a population-based cohort study | Maria Angeliki Toli |
| P2-06-01: CBP/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in TNBC | Xueying Yuan |
| P2-06-02: Identification of Antigenic Determinants in SV-BR-1 derived Cellular Breast Cancer Vaccines | Miguel Lopez-Lago |
| P2-06-03: Age Conditions the Tumor Microenvironment of Hormone Receptor Positive Breast Cancer | Mackenzie Hawes |
| P2-06-04: Potential Impact of the Cancer-Associated Fibroblast Secretome in the Tumor Microenvironment | Anjali Agrawal |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| P2-06-05: Use of breast adipose-derived stromal cells in a 3D spheroid model to recapitulate the triple-negative breast cancer tumor microenvironment | Nicole Cullen |
| P2-06-06: The Role of iNOS Inhibition in Enhancing Chemotherapy Efficacy by Modulating the Tumor Microenvironment in Obese TNBC Models | Ivonne Uzair |
| P2-06-07: Function of NR4A1 in Natural Killer Cells | Kenneth Martinez-Algarin |
| P2-06-08: A Novel SERM Reinvigorates Natural Killer Cells by Uniquely Downregulating DKK1 in Breast Cancer Cells | Kristen Young |
| P2-06-09: Impact of lipid composition on triple-negative breast cancer progression and survival. | Khudeja Salim |
| P2-06-10: The transcription factor HLF (Hepatic Leukemia Factor) : a potential therapeutic target in triple negative breast cancer | Ibrahim BOUAKKA |
| P2-06-11: TBK1 Promotes Growth of Aggressive Breast Cancer by Modulating the Tumor Microenvironment | Lan Phi |
| P2-06-12: MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity | Junlong Chi |
| P2-06-13: HOXB13 Expression Induces an Immunosuppressive Tumor Microenvironment in Breast Cancer | Dennis Sgroi |
| P2-06-14: Calcium-Sensing Receptor Agonist Enhanced Anti-Tumor Activity of Adoptive NK Cell Therapy in Triple-Negative Breast Cancer | Yu Shi |
| P2-06-15: DCIS-associated myoepithelial cells drive transcriptional alterations in macrophages through up-regulation of integrin $\alpha\beta6$ | Michael Allen |
| P2-06-16: Addressing Thermal and Battery Efficiency in AI Enhanced Portable Ultrasound Screening Protocols for Breast Cancer | Nusrat Zaman Zemi |
| P2-06-17: An Integrated Analysis of Metastatic Gene Co-expression in Triple-Negative Breast Cancer via Bulk and Single-Cell Transcriptome Data | Melody Hong |
| P2-06-18: Deep learning-based tumor microenvironment signature predicts progression-free survival in early-stage hormone receptor positive and HER2 negative breast cancer | Firas Khader |
| P2-06-19: The clinical relevance of infiltrating hematopoietic stem cells in the breast cancer tumor microenvironment | Masanori Oshi |
| P2-06-20: Use of an AI Algorithm to Determine the Prevalence of Breast Arterial Calcifications in Women Undergoing Screening Mammograms Based on Race, Age and Cancer Status | Chirag Parghi |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| P2-06-21: Preliminary validation of a multi-modal AI for stratification of early-stage breast cancer patients utilizing a foundation model for digital pathology | Jan Witowski |
| P2-06-22: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc. | Reshma L. Mahtani |
| P2-06-23: Using a Machine Learning Model for Prediction of Palbociclib Response in a Single Institution, Real-World Analysis of Patients with ER+ HER2- Advanced Breast Cancer | Xiaojie Zhang |
| P2-06-24: Effect of an Image-Derived Short Term Breast Cancer Risk Score in the Analysis of Breast Cancer Prevalence in Screening Population by Race and Breast Density | Chirag Parghi |
| P2-06-25: Is Mammography Artificial Intelligence consistent across race and density? | Chirag Parghi |
| P2-06-26: nf-hlamajority: a Nextflow pipeline for consensus MHC class I typing and its application to neoantigen identification in breast cancer stromal cells | Kevin Ryan |
| P2-06-27: Mapping APOBEC Profiles in Breast Cancer Microenvironments: Bridging Bulk and Single-Cell RNA-seq Data | Jake Lehle |
| P2-06-28: AI-driven feature discovery enables accurate identification of breast cancer biomarkers and histology | Joseph Cappadona |
| P2-06-29: Automated Breast Density Assessment on Chest CT with a Deep-Learned 3D Ordinal Regression Model | Artur Wysoczanski |
| P2-06-30: A Machine Learning Platform for In Silico Design of DNA Targeting Cancer Therapeutics Using SwRI's Rhodium® Docking Software | Tristan Adamson |
| P2-07-02: Predicting and validating up to 5-year risk of triple-negative breast cancer using mammogram images. | Graham Colditz |
| P2-07-03: Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP | Yifei Pei |
| P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study | Elizabeth McDonald |
| P2-07-05: Performance of the BCSC and MammoRisk (MR) scores with and without PRS313 to predict invasive breast cancer (IBC) risk in the UK Biobank cohort | Elie Rassy |
| P2-07-06: ClearCoast® MRI System - Intraoperative Magnetic Resonance Imaging for Margin Assessment of Ductal Carcinoma In Situ (DCIS) and Invasive Breast Cancer in Breast Conserving Surgery. MRO - A Controlled Post-Market Study | Marc Thill |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| P2-07-07: Multiparametric Whole-Body MRI for Reclassification of Oligometastatic Disease in Metastatic Breast Cancer Patients: A Prospective Study | Michela Palleschi |
| P2-07-08: MRI screening for brain metastases versus SYMptom-directed brain imaging for Patients with Triple neg or HER2+ Metastatic breast cancer: updated primary outcome analysis and preliminary quality of life data from a randomized phase II pilot study | Katarzyna J. Jerzak |
| P2-07-09: Breast cancer diagnosis using artificial intelligence algorithms | Yumi Kim |
| P2-07-10: The role of [18F]16 β -Fluoro-17 β -Fluoroestradiol (FES) Positron Emission Tomography (PET) in Predicting Response to Endocrine Therapy (ET) | Nicholas DiGregorio |
| P2-07-11: The value of baseline staging tests in early stage breast cancer: A retrospective study from the Antwerp University Hospital | Christophe Van Berckelaer |
| P2-07-12: Associations between demographic and clinicopathologic characteristics and convolutional neural network-derived breast cancer risk scores among women with hormone receptor-positive breast cancer. | Julia McGuinness |
| P2-07-13: USE OF INDIGO CARMINE FOR DETECTING SENTINEL LYMPH NODES IN BREAST CANCER: INTERIM RESULTS OF A STUDY ON EFFICACY AND SAFETY | Mikhail Voronov |
| P2-07-14: Head-to-head comparison of the dual-targeting tracer [68Ga]Ga-RM26-RGD and [18F]FDG for PET imaging of breast cancer | Qingyao Shang |
| P2-07-15: Metabolic tumor burden measured by [18F]FDG PET/CT and outcomes of patients with HER2-negative mBC treated with sacituzumab govitecan or trastuzumab deruxtecan | Romain-David Seban |
| P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2-Metastatic Breast Cancer (MBC) | Janice Lu |
| P2-07-17: Palbociclib in women aged ≥ 70 years as first-line treatment for endocrine-sensitive Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative locally advanced or metastatic breast cancer: final results of PalomAGE | Elisabeth Carola |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| P2-07-18: Results from PALVEN: A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL2-Positive Metastatic Breast Cancer | Geoffrey Lindeman |
| P2-07-19: Health-Related Quality of Life with Sacituzumab Govitecan versus Treatment of Physician's Choice in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Meta-Analysis of TROPiCS-02 and EVER-132-002 Trials | Hope S. Rugo |
| P2-07-20: Sociodemographic Disparities in First-Line (1L) Treatment Patterns and Outcomes in Women With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Metastatic Breast Cancer (mBC) in the United States (US) | Gregory Vidal |
| P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients | Nancy Chan |
| P2-07-22: Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study | Francois-Clement BIDARD |
| P2-07-23: Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A phase II randomized trial in PIK3CA-mutant hormone receptor-positive metastatic breast cancer | Sherry Shen |
| P2-07-24: Results from the Phase II Study of ROS1 Targeting with Crizotinib in Advanced E-cadherin Negative Lobular Breast Cancer (ROLo) | Alicia Okines |
| P2-07-25: Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression | Guilherme Nader-Marta |
| P2-07-26: Onvansertib shows synergistic efficacy in combination with paclitaxel in HR+ breast cancer: Mechanistic insights from preclinical models | Sreeja Sreekumar |
| P2-07-27: Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence | Ming-Feng Hou |
| P2-07-28: Treatment de-escalation by omission of chemotherapy & the effect of adding the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer—second interim efficacy analysis of the randomized DETECT V trial | Wolfgang Janni |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial | Fernando Moreno |
| P2-07-30: Exploring Treatment Options Following Progression to CDK4/6 Inhibitor in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis | Mariangela Gaudio |
| P2-08-01: Engaging breast cancer survivors in the United States in research: clinical characteristics and demographics from Susan G. Komen's ShareForCures® first cohort | Jessica Epps |
| P2-08-02: Effectiveness of cyclin inhibitors in patients with Hispanic metastatic breast cancer: Real-world evidence from the Instituto Oncológico Nacional in Panama | Omar Castillo-Fernandez |
| P2-08-03: Real-World Treatment Challenges in HR+/HER2- mBC: Results From the RETRACT Survey of 150 US Oncologists | Hope S. Rugo |
| P2-08-04: A Cohort Study of the effectiveness and tolerability of Trastuzumab Deruxtecan For The Treatment of Metastatic or Locally Advanced HER2-positive Breast Cancer. | Ameer Basta |
| P2-08-05: Pembrolizumab (P) added to Neoadjuvant Chemotherapy (NACT) for Triple Negative Breast Cancer (TNBC) in a community practice setting: Real World Evidence (RWE) for the effectiveness of the KN -522 regimen | Ramesh Ramanathan |
| P2-08-06: Comparative Analysis of Pathological Outcomes and Toxicity in Hispanic vs Non-Hispanic Patients Receiving Keynote 522 Regimen: A Retrospective Single Center Experience | Jay Parekh |
| P2-08-07: Benefit of neoadjuvant Pertuzumab/Trastuzumab therapy on pCR in Peruvian patients with HER2-Positive Breast Cancer | Iris Otoya, Zaida Morante |
| P2-08-08: Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer | Azadeh Nasrazadani |
| P2-08-09: Predictors of inadequate ovarian function suppression (OFS) in premenopausal women with hormone receptor (HR)-positive breast cancer receiving a gonadotropin-releasing hormone (GnRH) agonist in combination with endocrine therapy | Maryann Kwa |
| P2-08-10: Real World Use of Ovarian Function Suppression in Women Younger Than 35 with Early Stage ER+Her2- Breast Cancer | Poornima Saha |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| P2-08-11: Real-world safety of sacituzumab govitecan in patients with advanced triple receptor-negative breast cancer in a tertiary centre in the United Kingdom | Emma Crewe |
| P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint [®] in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data | Adam Brufsky |
| P2-08-13: Effectiveness of Combined Neoadjuvant Pembrolizumab and Chemotherapy in Early Triple-Negative Breast Cancer: Real-World Evidence from Multiple Centers in Asia | Yu-Ting Lin |
| P2-08-14: Prognostic Value of Real-World Immunohistochemical Changes in Breast Cancer Following Neoadjuvant Chemotherapy | Marcelo Antonini |
| P2-08-15: From Clinical Trials to Real-World Practice: Treatment Regimens, Pathological Complete Response Rates, and the Addition of Platinum Salts in Patients with Triple- Negative Breast Cancer | Stephan Seitz |
| P2-08-16: Comparative effects of Ribociclib, Palbociclib, and Abemaciclib on circulating and tumor infiltrating myeloid cells in metastatic breast cancer patients | Nikhila Kethireddy |
| P2-08-18: De-Escalating Axillary Surgery in Nigeria: a phase II Single Arm Trial Protocol | Gregory Knapp |
| P2-08-19: Delineating The Role of Normal Cell Types In Breast Cancer (Breast Cell Atlas) | Nelly Hernandez |
| P2-08-20: ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study | Virginia Kaklamani |
| P2-08-21: ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study | Aditya Bardia |
| P2-08-22: Effectiveness and implementation of a decision support tool to improve surgical decision-making in young women with breast cancer: The CONSYDER Study | Shoshana Rosenberg |
| P2-08-23: Evaluation of Pathological Complete Response & Immunomodulatory Effects Following Intratumoral Injection of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: A Phase II Study INVINCIBLE-4-SAKK 66/22 | Ursina Zürrer-Härdis |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| P2-08-24: Exploring the correlation between Superparamagnetic Iron Oxide counts at the axilla and Ductal Carcinoma In Situ size after Primary Breast Surgery: Preliminary Study Results | Bernardo Martinez-Leal |
| P2-08-25: FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive/HER2 negative breast cancer | Coral Omene |
| P2-08-26: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer | Robert Maganini |
| P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd) | BARBARA PISTILLI |
| P2-08-28: Implementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older Breast Cancer patients (IMPORTANT trial) – a pragmatic randomized-controlled trial | Emanuela Risi |
| P2-08-29: Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study (LaPemERLA) | Yoon-Sim Yap |
| P2-09-01: Preliminary Findings from the Breast Cancer Combined Visualization And Characterization Tools (bCOMBAT): Low-Dose PEM and Liquid Biopsy Study | Vivianne Freitas |
| P2-09-02: Two Years Post-COVID-19: Evaluating the Impact on Brazil's Mammographic Screening Program | André Mattar |
| P2-09-03: USING OF SULPHUR HEXAFLUORIDE (SF6) FOR DETECTION OF SENTINEL LYMPH NODE IN OUTPATIENT PRACTICE: PRELIMINARY RESULTS FROM AN EFFICACY AND SAFETY STUDY | MARIIA SHARAVINA |
| P2-09-04: A Randomized Study Assessing Interventions to Improve Comfort During Screening Mammography | Nikki Verma |
| P2-09-05: Evaluating the Impact of Mammographic Screening on 5-Year Breast Cancer Survival: A Propensity Score-Adjusted Retrospective Cohort Study in a Tertiary Hospital in São Paulo, Brazil | Rodrigo Goncalves |
| P2-09-06: Bi-annual mammography does not detect more local recurrences than annual mammography in Asian female patients with breast cancer | Byeongju Kang |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| P2-09-07: Diagnostic performance of TILs-US Score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer | Hideo Shigematsu |
| P2-09-08: Correlating Breast Density with FDG-avidity on PET Imaging | YiLi Zhao |
| P2-09-09: Image-based breast cancer risk assessment based on dense mammographic tissue subtypes | Andre Khalil |
| P2-09-10: Accuracy of stereotactic vacuum-assisted breast biopsy for investigating suspicious calcifications in 2,274 patients a Public Hospital in Brazil | André Mattar |
| P2-09-11: Improved Prediction of Axillary Lymph Node Metastasis in Early-Stage Breast Cancer Using Deep Learning on Routine Mammography | Daqu Zhang |
| P2-09-12: A Public Health Initiative To Enhance Screening Mammography (MMG) In Northeast Argentina Utilizing A Novel Thermal Screening Device & Breast Cancer Risk Assessment | Karina Maidana |
| P2-09-14: Diagnostic Accuracy assessing residual disease in breast cancer patients receiving neoadjuvant systemic therapies (NST) is comparable between contrast enhanced mammography(CEM)& breast magnetic resonance imaging(MRI) across various cancer subtypes | Whitney Harris |
| P2-09-16: A Phase 1b/2 study of palazestran (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer | Virginia Borges |
| P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/HER2- advanced breast cancer: the Linux trial | Lei Fan |
| P2-09-18: Comparison of Suboptimal vs. Adequate Ovarian Suppression during Adjuvant Endocrine Therapy for Premenopausal Women with Breast Cancer: An Exploratory Analysis of the PREFER and GIM 23 Studies | Simone Nardin |
| P2-09-19: Efficacy of cyclin-dependent kinase 4/6 inhibitor + endocrine therapy in patients w/ hormone receptor-positive, HER2-negative advanced or metastatic breast cancer w/ liver or lung only metastases: a US Food & Drug Administration pooled analysis | Raissa Kentsa |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| P2-09-20: Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2-advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials | Yoon-Sim Yap |
| P2-09-21: Low-level Aurora kinase A (AURKA) amplification as a novel personalized biomarker of CDK4/6 inhibitor (CDK4/6i) resistance in patients with hormone-receptor positive (HR+) metastatic breast cancer | Seth Wander |
| P2-09-22: First-line inavolisib/placebo + palbociclib + fulvestrant in PIK3CA-mutated, hormone receptor+, HER2- locally advanced/metastatic breast cancer w/ relapse during/within 12 months of adjuvant endocrine therapy completion: INAVO120 long-term safety | Cristina Saura |
| P2-09-23: Differential outcomes of patients with HR-positive/HER2-negative metastatic breast cancer and a pathogenic BRCA1/2 or PALB2 variant under first line CDK4/6 inhibition | Timothé Guinel |
| P2-09-24: Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial | Ana Garrido-Castro |
| P2-09-25: Subgroup Analyses From the Phase 3 EVER-132-002 Study of Asian Patients With HR+/HER2- Metastatic Breast Cancer | Joohyuk Sohn |
| P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 study | Claudio Vernieri |
| P2-09-27: Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor-positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409) | Darian Louthan |
| P2-09-28: Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer: a multicenter, prospective, external controlled phase 2 study | Hongnan Mo |
| P2-09-29: Landscape analysis of breast cancer ovarian metastases reveals biology and potential therapeutic targets | Steffi Oesterreich |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| P2-09-30: Real-world comparative efficacy of CDK4/6 inhibitors in first-line treatment of HR+/HER2- metastatic breast cancer | Adam Brufsky |
| P2-10-01: Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population | Bo-Fang Chen |
| P2-10-02: SACISUR, results of a real-world evidence observational study of the use of Sacituzumab-Govitecan (SG) in triple negative metastatic breast cancer (mTNBC) clinical practice in the south of Spain. | Alejandro Falcón-González |
| P2-10-03: Real world outcomes of adjuvant chemotherapy in invasive lobular carcinoma of the breast: a retrospective cohort from a reference center in Brazil | Raelson Miranda |
| P2-10-04: Effectiveness and toxicity profile of pertuzumab in combination with trastuzumab and taxane in patients with HER2 positive metastatic breast cancer treated in the Costa Rican Health Care System | Priyanka Khanna |
| P2-10-05: Survival in Older Women Receiving Adjuvant Radiation Monotherapy vs. Endocrine Monotherapy Following Lumpectomy | Jennifer Plichta |
| P2-10-06: Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: a multicentre international retrospective cohort study | Luca Visani |
| P2-10-07: Practice patterns and survival analysis of early-stage HER-negative breast cancers with low and intermediate levels of hormone receptor expression: a 2018-2020 US National Cancer Database analysis | Dionisia Quiroga |
| P2-10-08: The Impact of Time-to-Surgery (TTS) for Breast Cancer Prognosis After Neoadjuvant Chemotherapy | Xin Wang |
| P2-10-09: Can an AI-based Clinical Decision Support System (CDSS) in the treatment decision-making process for breast cancer contribute to healthcare cost reduction ? | Barbara Bussels |
| P2-10-10: Integration of Novel Antibody–Drug Conjugates in Advanced HER2-low, Hormone Receptor-positive and Triple-negative Breast Cancer | Kemi Obajimi |
| P2-10-11: Utilization and impact of endocrine therapy in male patients with early breast cancer – results from a large German real-world claims data analysis | Dominik Dannehl |
| P2-10-12: Pembrolizumab in Early Triple-negative breast cancer: Real world data in Hispano-American women (PETRHA) - Initial results | Daniela Vazquez-Juarez |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| P2-10-13: The Real World Practice of Prospectively Breast Cancer Screening Program for High Polygenic Risk Score Population in Taiwan | Yu-Wen Weng |
| P2-10-14: HER2 evolution in breast cancer: Evidence from an AI-assisted real-world data analysis of 3 million women in a diverse urban population | Francisco Esteva |
| P2-10-15: Reproducibility of the interactions of race on outcomes and toxicities associated with treatment of HER2+ Breast Cancer across databases | Britney Fitzgerald |
| P2-10-16: A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT) | Ting Bao |
| P2-10-17: A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician's choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01) | Pedram Razavi |
| P2-10-18: A study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral SARM, as monotherapy and in combination with standard of care regimens in patients with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer | Joyce O'Shaughnessy |
| P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer | Ciara O'Sullivan |
| P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd) | Joyce O'Shaughnessy |
| P2-10-21: ADELA: A randomized, phase 3, double-blind, placebo-controlled trial of elacestrant plus everolimus versus elacestrant in ER+/HER2-advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) plus CDK4/6i | Antonio Llombart-Cussac |
| P2-10-22: APOBEC3 as a Biomarker of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Pilot Study | Iman Doostan |
| P2-10-23: ASSESSING CLINICAL FEATURES AND OUTCOME OF BREAST CANCER IN PALB2 MUTATION CARRIERS: AN EUROPEAN MULTICENTRIC RETROSPECTIVE HOSPITAL-BASED COHORT CONTROL STUDY (PALBREAST) | Laura Cortesi |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| P2-10-24: ASTRO-VAC CNS : Bria-IMT in the Management of Tumor Agnostic Metastatic CNS Lesions | Sailaja Kamaraju |
| P2-10-25: AXSANA: Status of the international prospective multicenter cohort study evaluating different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655) | Steffi Hartmann |
| P2-10-26: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breast cancer with high stromal tumor-infiltrating lymphocytes (sTILs) score (ETNA) | Elie Rassy |
| P2-10-27: An Open Label Study of BTX-A51 in Patients with ER+/HER2- GATA3 Mutant and Wild Type Metastatic Breast Cancer | Zung Thai |
| P2-10-28: COMPASS-TNBC - A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety and anti-tumor activity of novel therapeutics in patients with early relapsed mTNBC. Module 1: Dato-DXd & Module 2: Dato-DXd + durvalumab. | Thomas Grinda |
| P2-10-29: Cascade Testing in Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE) | Alissa Michel |
| P2-10-30: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients with HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade - CHERRY-PICK Trial (LACOG 0721) | Sérgio Daniel Simon |
| P2-11-01: Comprehensive spatially resolved single-cell analysis of immunotypes in triple-negative breast cancer revealed the central role of intratumoral MHC class II expressions | Yi Liu |
| P2-11-02: Is Adjuvant Chemotherapy Needed in Small Node-Negative Triple Negative Breast Cancer? | Joon Suk Moon |
| P2-11-03: Quantification of Breast Cancer 1 gene (BRCA1) promoter methylation in individuals with and without cancer using cell-free DNA | Francesca Menghi |
| P2-11-04: Incidence and pattern of central nervous system recurrence in TNBC according to response after neoadjuvant treatments | Thomas Grinda |
| P2-11-05: Accurate and cost-effective reconstruction of TNBC heterogeneity through 3D digitization of core needle biopsies | Jeffrey Sheridan |
| P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial | Li Chen |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| P2-11-07: Open | |
| P2-11-08: Spatial transcriptomic analysis for tumor infiltrating immune microenvironment modulation by neoadjuvant pembrolizumab with chemotherapy for patients with triple negative breast cancer | Ji-Yeon Kim |
| P2-11-09: Adding Carboplatin to neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC): a systematic review and meta-analysis | Beatrice Ruffilli |
| P2-11-10: Assessing the Differential Response to Immunotherapy in BRCA1/2 Mutation Carriers with Triple-Negative Breast Cancer | Minna Lee |
| P2-11-11: Clinicopathological features predictive of neoadjuvant immune checkpoint inhibitor benefit in triple-negative breast cancer | Shipra Gandhi |
| P2-11-12: Use of the prognostic H&E stromal tumor-infiltrating lymphocytes score and the predictive 27-gene IO score to identify patients with stage I TNBC who may benefit from immune checkpoint inhibitor-based, chemo de-escalated curative-intent therapy. | Erin Hong |
| P2-11-13: Retrospective validation of digital twin-based prediction of personalized triple negative breast cancer response to neoadjuvant therapy regimens | Chengyue Wu |
| P2-11-14: Treatment Patterns and Safety of Adjuvant Therapy After Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer in a Real-World Scenario: The Neo-Real Study | Renata Bonadio |
| P2-11-15: Axillary Pathologic Complete Response in Triple-Negative Breast Cancer Patients with Mammary Pathologic Complete Response: A Systematic Review | Yedda Reis |
| P2-11-16 Characterization of disseminated tumor cells (DTCs) in patients with triple-negative breast cancer (TNBC) | Anne Eckardt |
| P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial | Hans-Christian Kolberg |
| P2-11-18: Patterns of Treatment in Older Patients with Early-Stage Triple Negative Breast Cancer | Mohammad Abbas |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| P2-11-19: Unique kinetics of myeloid derived suppressor cell (MDSC) accumulation associated with immune related adverse events (irAEs) in patients with early stage triple negative breast cancer (eTNBC) receiving neoadjuvant chemo-immunotherapy | Alberto Montero |
| P2-11-20: Discovering Co-driver Genes and Pathways of Mutant TP53 in Breast Cancer by CRISPR Screening and Multi-omics Approaches | Lilian Nwachukwu |
| P2-11-21: Characterisation of treatment and outcomes for adenoid cystic carcinoma as a distinct clinical sub-type of triple negative breast cancer | Fiona Britton |
| P2-11-22: Tolerance of Neoadjuvant Chemotherapy in Combination with Immunotherapy in Older Patients with Triple Negative Breast Carcinoma: The MSKCC Experience | Abha Kulkarni |
| P2-11-23: Impact of age on neoadjuvant chemo-immunotherapy (IO) administration and outcomes in patients with early-stage triple-negative breast cancer (TNBC) | Alexis LeVee |
| P2-11-24: Racial and ethnic disparities in treatment outcomes of patients with early-stage triple-negative breast cancer following neoadjuvant chemoimmunotherapy | Megan Wong |
| P2-11-25: Comparison of Outcomes Among Women with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy According to Age | Regina Matar-Ujvary |
| P2-11-26: Adjuvant chemotherapy in lymph node-negative, T1 triple-negative breast cancer | Jesus anampa |
| P2-11-27: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab vs. Treatment of Physician's Choice in Patients With TNBC Who Received Neoadjuvant Therapy & Did Not Achieve a Pathological Complete Response at Surgery | Heather McArthur |
| P2-11-28: Intra-arterial chemotherapy for triple-negative breast cancer: a systematic review | Mariano Belfort Santos |
| P2-11-29: IMPACT OF GERMLINE MUTATIONS ON pCR IN TRIPLE NEGATIVE BREAST CANCER PATIENTS TREATED WITH PEMBROLIZUMAB PLUS CHEMOTHERAPY: THE TIGER STUDY | Andrea Botticelli |
| P2-11-30: RAD51AP1 Inactivation Induces Synthetic Lethality of PARP Inhibitors in Breast Cancer Patients Irrespective of BRCA1/2 mutation | Jabunnesa Khanom |
| P2-12-01: Survival Outcomes after Pathologic Complete Response with Neoadjuvant Endocrine Therapy vs. Neoadjuvant Chemotherapy | Jennifer Plichta |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| P2-12-02: Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database | Paolo Tarantino |
| P2-12-03: The effect of Abemaciclib plus fulvestrant on overall survival in hormone-receptor positive, HER2-negative breast cancer that progressed on endocrine therapy – Comparing Real-World outcomes in England to MONARCH 2 | Emma Kipps |
| P2-12-04: Impact of Weight and Weight Variation in Adolescent and Young Adult (AYA) Women with Invasive Breast Cancer | Nerea Lopetegui-Lia |
| P2-12-05: Retrospective Study of Drug-Induced Interstitial Lung Disease in Breast Cancer Patients Treated at Mayo Clinic between the Years of 2018-2023 (Real World Experience) | John Fanous |
| P2-12-06: Key factors influencing patient preferences for BRCA testing and adjuvant therapy in HER2-negative early breast cancer | Kathryn Mishkin |
| P2-12-07: Effectiveness of Predictive Calculators for Breast Cancer Recurrence: A Comparative Study with the 21-Gene Score | Iris Otoyá |
| P2-12-08: Real world progression-free survival after CDK4/6 inhibitors plus endocrine therapy: results from the multicenter SISTER study | Pier Paolo Maria Berton Giachetti |
| P2-12-09: Clinical, genetic and immunological features, HER2-low expression and treatment patterns in a large population of male breast cancer patient with long-term follow up | Fabio Giardi |
| P2-12-10: Dynamic Changes in Breast Cancer Immunochemistry Biomarkers at Recurrence and Their Impact on Survival | Katia Roque |
| P2-12-11: Lobular breast cancer: diagnostic complexity and delays to surgery. | Hannah Lennon |
| P2-12-12: Impact of the addition of pembrolizumab to neoadjuvant chemotherapy in triple negative breast cancer in Ireland: a retrospective, multi-centre, real-world study | Karine Ronan |
| P2-12-13: Clinico-Pathological Characteristics and Incidence Trends of Breast Cancer in Young Women: A 10-Year Single Institution Retrospective Study | Francisco Javier Muñoz i Carrillo |
| P2-12-14: Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer | Jessica Sharpe |
| P2-12-15: Trends in Antiemetic Use in Patients Receiving Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer: A Retrospective Analysis of Data from the IntegraConnect PrecisionQ De-Identified Database | Stephan Rosenfeld |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| P2-12-16: A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED TRIAL EVALUATING EFFECT OF A WIDE SPECTRUM MICRONUTRIENTS SUPPLEMENT ON CANCER RELATED FATIGUE IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT/NEO-ADJUVANT THERAPY | Germano Tarantino |
| P2-12-17: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors | Yara Abdou |
| P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE) | Matthew Goetz |
| P2-12-19: A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions | Julie Nangia |
| P2-12-20: A Real-World Study of the Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in HER2-low Metastatic Breast Cancer (mBC) among Racial and Ethnic Minorities and Older Populations in the United States | Mackenzie Henderson |
| P2-12-21: A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Metastatic Breast Cancer: Primary Results of a Prospective Intervention Trial | Deloris Veney |
| P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer. | Jie Ouyang |
| P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE) | Francois-Clement BIDARD |
| P2-12-24: A phase I/Ib trial of the CDK4/6 antagonist ribociclib and the HDAC inhibitor belinostat in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE). | Talicia Savage |
| P2-12-25: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007 | Julia White |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| <p>P2-12-26: A phase Ib study of novel combination (New) of low dose oral cyclophosphamide (S) To potentiate axatilimab (A) + retifanlimab (R) in treating metastatic Triple negative breast cancer (NEW START)</p> | <p>Joshua Haney</p> |
| <p>P2-12-27: A phase Ib study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in patients with refractory HER2-positive metastatic breast cancer.</p> | <p>Santiago Escrivá-de-Romaní</p> |
| <p>P2-12-28: A prospective randomized, controlled study to evaluate device efficacy for cutting and/or coagulation of tissue during mastectomy procedures.</p> | <p>Jessica Montalvan</p> |
| <p>P2-12-29: A randomized clinical trial comparing ctDNA-directed therapy change with standard of care in patients with metastatic triple negative breast cancer (mTNBC)</p> | <p>Jessica Sharpe</p> |
| <p>P2-12-30: A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT)</p> | <p>Ting Bao</p> |